Bio-Techne Corporation
TECH
주식 순위
#1867
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
주가
$72.51
시가총액
$11.37B
변동 (1일)
-0.09%
변동 (1년)
17.21%
국가
US
거래 Bio-Techne Corporation (TECH)
카테고리
Healthcare
Bio-Techne Corporation (TECH)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 61.97
Bio-Techne Corporation의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 61.97입니다. 2024년 말 기준 P/E 비율은 67.18였습니다.
Bio-Techne Corporation의 P/E 비율 기록 (2000 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 61.97 | -43.88% |
| 2025 | 110.41 | 64.35% |
| 2024 | 67.18 | 49.36% |
| 2023 | 44.98 | -9.99% |
| 2022 | 49.97 | -59.78% |
| 2021 | 124.26 | 182.43% |
| 2020 | 44.00 | -46.54% |
| 2019 | 82.30 | 86.05% |
| 2018 | 44.24 | -22.03% |
| 2017 | 56.74 | 41.34% |
| 2016 | 40.14 | 18.38% |
| 2015 | 33.91 | 10.18% |
| 2014 | 30.78 | 34.96% |
| 2013 | 22.80 | -6.55% |
| 2012 | 24.40 | -11.39% |
| 2011 | 27.54 | 41.26% |
| 2010 | 19.49 | -14.94% |
| 2009 | 22.92 | -21.66% |
| 2008 | 29.25 | 10.46% |
| 2007 | 26.48 | -2.30% |
| 2006 | 27.11 | -3.27% |
| 2005 | 28.02 | -16.81% |
| 2004 | 33.69 | 21.76% |
| 2003 | 27.67 | -35.05% |
| 2002 | 42.59 | 7.61% |
| 2001 | 39.58 | -60.15% |
| 2000 | 99.34 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 28.78 | -53.55% |
US
|
|
| -28.36 | -145.76% |
US
|
|
| -24.57 | -139.65% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -51.05% |
NL
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.